Objective: To compare the mortality rates of patients with claudication and de novo femoropopliteal lesions treated with and without paclitaxel coated devices (PCD).
Background: A recent meta-analysis, mostly including patients with claudication and de novo femoropopliteal lesions but also with recurrent stenoses and critical limb ischemia, has shown a significant excess mortality in patients treated with PCD.
Methods: Comparison of two historical cohorts of patients presenting with claudication and de novo femoropopliteal lesions treated with and without PCD between 2008 and 2018.
Results: After review of 5219 arteriograms in patients presenting with peripheral artery disease, 700 consecutive patients were included consisting in 72.6% of male (n = 508). Mean age was 68.1 ± 8.5 years. 45.7% of the patients (n = 320) had a treatment including a PCD. Mean femoropopliteal lesion length was 123 ± 91 mm including 44.6% of occlusions. Patients of the control group were censored at crossover to paclitaxel when applicable. Mortality rates at 1, 2 and 5 years were 4.6%, 7.5%, 19.4% and 1.6%, 6.2%, 16.6% in the non-PCD and PCD groups respectively. The relative risks of death when using PCD were 0.35 (p = 0.03), 0.83 (p = NS) and 0.86 (p = NS) at 1, 2 and 5 years respectively.
Conclusion: There was no excess mortality in patients with claudication and de novo femoropopliteal lesions treated with paclitaxel coated devices at 1, 2 and 5 years of follow-up in this cohort. The current study suggests that additional prospective randomized studies properly powered to study mortality are necessary.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382808 | PMC |
| http://dx.doi.org/10.1186/s42155-021-00255-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lesion Localization and Limb Outcomes in Elderly Patients with and Without Type 2 Diabetes Mellitus Who Undergo Atherectomy-Assisted Endovascular Revascularization due to Symptomatic Peripheral Artery Disease.
J Clin Med
October 2024
Cardiology and Vascular Medicine, GRN Hospital Weinheim, 69469 Weinheim, Germany.
Type 2 diabetes mellitus (T2DM) represents a major risk factor for peripheral artery disease (PAD). We aimed to evaluate the impact of T2DM on lesion localization and complexity, clinical presentation by Rutherford categories, and limb outcomes in elderly patients with symptomatic PAD undergoing endovascular revascularization. Five hundred consecutive patients with symptomatic infra-inguinal PAD who underwent rotational atherectomy-assisted endovascular revascularization were included.
View Article and Find Full Text PDFDesign and Baseline Characteristics of the STRIDE Trial: evaluating Semaglutide in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes.
Eur Heart J Cardiovasc Pharmacother
October 2024
Division of Cardiovascular Surgery, St. Michael's Hospital, University of Toronto, Toronto, Canada.
Article Synopsis
- The STRIDE trial is testing the effects of semaglutide, a GLP-1 receptor agonist, on improving walking distance and functional ability in people with peripheral artery disease (PAD) and type 2 diabetes (T2D).
- The study includes 792 participants across 20 countries, primarily older adults with significant health risks and functional impairments related to their conditions.
- Results from this trial aim to clarify whether semaglutide can enhance quality of life and physical performance in this patient population.
A newly discovered anatomical abdominal aorta anomaly; "Arax anomaly".
Int J Surg Case Rep
November 2024
Shiraz University of Medical Sciences, Fars, Iran. Electronic address:
Article Synopsis
- The abdominal aorta is a part of a big blood vessel in the body that can have different shapes while growing in the womb.
- A 35-year-old woman with diabetes had a successful surgery after experiencing stomach pain and leg pain when walking.
- Doctors found a rare and unusual blood vessel connection, which has never been seen before, and they suggest that it's important to carefully check blood vessels before any medical procedure.
In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme.
Eur J Prev Cardiol
November 2024
Université Paris-Cité, AP-HP, Hôpital Bichat, and FACT, INSERM U-1148/LVTS, Paris, France.
Introduction: Inclisiran, an siRNA targeting hepatic PCSK9 mRNA, administered twice-yearly (after initial and 3-month doses), substantially and sustainably reduced LDL-cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a reduced risk of major adverse cardiovascular events (MACE) is not yet established. In-silico trials applying a disease computational model to virtual patients receiving new treatments allow to emulate large scale long-term clinical trials.
View Article and Find Full Text PDFCharacterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health study.
Am Heart J
September 2024
Department of Medicine, Duke University School of Medicine, Durham, NC.
Article Synopsis
- - This study investigates the characteristics and immunophenotypic profiles of individuals with peripheral artery disease (PAD) using data from the Project Baseline Health Study, highlighting a lack of previous research in this area.
- - Out of 2,209 participants, only a small percentage (2.6%) had PAD, with various comorbidities like smoking, hypertension, and diabetes being significantly higher in those with the disease compared to participants with normal ankle brachial indices.
- - The findings suggest that PAD may be underdiagnosed, particularly among women and Black or African American individuals, and propose that the identified immunophenotypic profile could aid in the early diagnosis of PAD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!